Edition:
United States

Recipharm AB (publ) (RECIb.ST)

RECIb.ST on Stockholm Stock Exchange

97.75SEK
20 Oct 2017
Change (% chg)

-0.75kr (-0.76%)
Prev Close
98.50kr
Open
98.25kr
Day's High
98.50kr
Day's Low
97.50kr
Volume
40,927
Avg. Vol
119,438
52-wk High
140.00kr
52-wk Low
84.25kr

Latest Key Developments (Source: Significant Developments)

Recipharm starts cooperation with Roche
Wednesday, 20 Sep 2017 01:45am EDT 

Sept 20 (Reuters) - RECIPHARM AB (PUBL) :RECIPHARM SIGNS LONG-TERM MANUFACTURING AGREEMENT WITH MAJOR NEW CUSTOMER AND ACQUIRES FACILITY IN SPAIN.‍ENTERED INTO COLLABORATION WITH ROCHE​.‍WILL ALSO ACQUIRE A MANUFACTURING FACILITY CURRENTLY EMPLOYING APPROXIMATELY 200 PEOPLE LOCATED IN LEGANÉS, SPAIN, FROM ROCHE​.‍LONG-TERM AGREEMENT WILL ADD ANNUAL SALES OF ABOUT EUR 35 MILLION CORRESPONDING TO MORE THAN 6% OF CURRENT GROUP SALES​.‍CLOSING OF TRANSACTION AND COMMENCEMENT OF SUPPLY UNDER AGREEMENT IS ANTICIPATED BY YEAR END 2017.​.  Full Article

Recipharm, Kancera cooperate to manufacture clinical trial supply
Thursday, 14 Sep 2017 02:30am EDT 

Sept 14 (Reuters) - RECIPHARM AB (PUBL) :RECIPHARM AND KANCERA <<>> COLLABORATE TO MANUFACTURE CLINICAL TRIAL SUPPLY.‍AS PART OF COLLABORATION, CO TO DEVELOP PREPARATION THAT IS REQUIRED FOR RELEASE OF KAND567 FROM CAPSULES AND MANUFACTURING PHARMACEUTICAL PRODUCT​.  Full Article

Recipharm Q2 EBITDA SEK 242 million
Tuesday, 25 Jul 2017 01:45am EDT 

July 25 (Reuters) - RECIPHARM AB (PUBL) :Q2 NET SALES SEK ‍1.40 BILLION VERSUS SEK 1.24 BILLION YEAR AGO​.Q2 EBITDA SEK 242 MILLION VERSUS SEK 240 MILLION YEAR AGO.‍I'M CONFIDENT THAT OUR LONG-TERM OBJECTIVES WILL BE ACHIEVED - CEO​."‍CERTAIN DELAYS ARE CAUSING SOME UNCERTAINTY AND TOGETHER WITH NON-RECURRING COSTS IN Q1 THIS MAY MAKE IT A BIT OF A CHALLENGE TO FULLY REACH MARGIN TARGET FOR 2017."​.RECIPHARM -CERTAIN DELAYS ARE CAUSING UNCERTAINTY AND NON-RECURRING COSTS IN Q1 MAY MAKE IT CHALLENGE TO REACH 2017 MARGIN TARGET​.  Full Article

Recipharm EBITDA margin falls to 12 pct in Q1
Thursday, 27 Apr 2017 01:45am EDT 

April 27 (Reuters) - Recipharm AB (Publ) :Q1 net sales amounted to SEK 1,328 million (973), an increase of 37 pct.Q1 EBITDA SEK 159 million (136) corresponding to an EBITDA margin of 12 pct (14).Says despite an exceptionally weak start of year profit wise, underlying business is developing according to our plans and we maintain our sales growth and ebitda-margin objectives along with our leverage targets.Says confident that these objectives will be achieved.  Full Article

Recipharm appoints Henrik Stenqvist as new CFO
Tuesday, 11 Apr 2017 01:45am EDT 

Recipharm :Recipharm appoints Henrik Stenqvist as new Chief Financial Officer.  Full Article

Recipharm Q4 EBITDA 229 mln SEK
Thursday, 23 Feb 2017 01:45am EST 

Recipharm AB : Q4 net sales amounted to sek 1 333 million (863), an increase of 54% . Recipharm ab (publ) says proposed share dividend is sek [1.50] (1.50) per share . Q4 ebitda increased by 108% and amounted to sek 229 million (110) .Recipharm ab (publ) says we are well on track to reach our long-term financial targets and overall objectives.  Full Article

Recipharm places SEK 1,000 mln convertible bonds
Thursday, 29 Sep 2016 12:00pm EDT 

Recipharm Ab (Publ) : Says places SEK 1,000 million senior unsecured convertible bonds .Says the bonds will carry a coupon of 2.75 pct per annum, and have a conversion price set at SEK 181.955.  Full Article

Recipharm H1 EBITDA up 20 pct
Friday, 22 Jul 2016 01:51am EDT 

Recipharm Publ Ab : Jan-Jun net sales amounted to sek 2 208 million (1 742), an increase of 27 % . Jan-Jun ebitda increased by 20 % and amounted to sek 376 million (314) giving an ebitda margin of 17.0 % (18.0) . Says going forward i expect our growth-driving strategies, including executing on further acquisition opportunities, to continue to deliver Further company coverage: [RECIb.ST] (Reporting By Johan Ahlander) ((johan.ahlander@thomsonreuters.com;)).  Full Article

Recipharm creates global CDMO leader through SEK 1.7 bln acquisitions
Monday, 18 Apr 2016 01:10am EDT 

Recipharm publ AB:Recipharm creates a global CDMO leader through SEK 1.7 billion strategic acquisitions in the US, Sweden and India.Recipharm says signed two separate agreements to acquire Kemwell's pharmaceutical contract development and manufacturing (cdmo) businesses.Recipharm says proposed share issue of approximately sek 850 million with preferential rights for existing shareholders.Recipharm says businesses to be acquired had 2015 preliminary net sales of approximately sek 745 million, corresponding to 22 per cent of Recipharm's 2015 total net sales.Recipharm says acquisitions are expected to be accretive to ebitda margin already from 2016 and are well in line with Recipharm's overall financial objectives.The acquisition price for Kemwell's operations in the US and Sweden amounts to approximately USD 85 million (SEK 693 million) on a cash and debt free basis.Closing of the transaction is expected to take place during the second quarter of 2016.The acquisition price for the operations in India amounts to USD 120 million (SEK 982 million) on a cash and debt free basis.  Full Article

Recipharm publ AB prposes a dividend for FY 2015, sets new objectives
Wednesday, 24 Feb 2016 01:45am EST 

Recipharm publ AB:Proposed share dividend is 1.50 (1.25) crown per share​ for FY 2015.New objectives are to reach sales of at least 8 billion crowns by 2020, to have an EBITDA margin of at least 16 pct and to have a net debt to equity ratio less than 0.8​.Objective that 30-50 pct of profit after tax should be distributed as dividend to shareholders remains unchanged​.  Full Article

BRIEF-Recipharm starts cooperation with Roche

* RECIPHARM SIGNS LONG-TERM MANUFACTURING AGREEMENT WITH MAJOR NEW CUSTOMER AND ACQUIRES FACILITY IN SPAIN